Expert Interview
Delving into the results from the head to head trial between orforglipron from Eli Lilly and oral semaglutide from Novo Nordisk in diabetes and obesity.
Ticker(s): LLY, NVOInstitution: University of California at San Diego
- Board-certified Obesity Medicine Physician and Medical Director for the Weight Management Program at UC San Diego Health
- Treats over 100 patients per year with obesity with a variety of methods including surgery, medication, nutrition, behavior, and lifestyle support.
- Clinical interest in metabolism, weight regulation, treatment of obesity and weight-related medical conditions; Research interests include anti-obesity medications, obesity medicine education and bariatric surgery.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
